.png){kind=icon}
返回
Data Challenges for Externally Controlled Trials: Viewpoint
.png){kind=icon}
OA
AI
DOI：10.2196/43484.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
The preferred evidence of a large randomized controlled trial is difficult to adopt in scenarios, such as rare conditions or clinical subgroups with high unmet needs, and evidence from external sources, including real-world data, is being increasingly considered by decision makers. Real-world data originate from many sources, and identifying suitable real-world data that can be used to contextualize a single-arm trial, as an external control arm, has several challenges. In this viewpoint article, we provide an overview of the technical challenges raised by regulatory and health reimbursement agencies when evaluating comparative efficacy, such as identification, outcome, and time selection challenges. By breaking down these challenges, we provide practical solutions for researchers to consider through the approaches of detailed planning, collection, and record linkage to analyze external data for comparative efficacy.
Keyword:
external control arm
synthetic control arm
single-arm trial
real-world evidence
regulatory approval
data
clinical
decision-making
efficacy
rare conditions
trial
期刊
IF:
6
论文数:
9.7K
被引数:
5.0W
机构
引用论文
Sierra Nevada, California, U.S.A., Snow Algae: Snow Albedo Changes, Algal-Bacterial Interrelationships, and Ultraviolet Radiation Effects美国加利福尼亚州内华达山脉，雪藻: 雪反照率变化，藻类-细菌相互关系和紫外线辐射效应
PREAI
分享收藏The external validity of published randomized controlled trials in primary care.png)
BMC FAMILY PRACTICE
OAAI
BMC FAMILY PRACTICEIF3.2
OAAI分享收藏A call for an integrated approach to improve efficiency, equity and sustainability in rare disease research in the United StatesNATURE GENETICSOAAI
NATURE GENETICSIF31.8
OAAI分享收藏分享收藏
查看更多内容